Article Figures & Data
Figures
- Fig 1.
Overall survival and progression-free survival probability based on ADC or rCBV measurements. A and D, Patient outcome as a function of ADCmin stratification into low and high groups. Kaplan-Meier analysis (A) of OS for patients stratified into the low group (ADCmin < 384, dashed line) with a mean survival of 12.1 months versus those stratified into the high group (ADCmin ≥ 384, solid line) with a mean survival time of 20.1 months (P = .02, logrank test). Kaplan-Meier plot (D) of PFS stratified into the same low group (ADCmin < 384, dashed line) with a mean progression time of 13.8 months versus those stratified into the high group (ADCmin ≥ 384, solid line) with a mean progression time of 38.9 months (P < .01, logrank test). B and E, Patient outcome as a function of rCBVmean shows a statistically significant difference in OS and PFS between low (rCBVmean < 1.43) and high (rCBVmean ≥ 1.43) groups (P = .03, logrank test for OS; P = .03, logrank test for PFS). C and F, Patient outcome as a function of rCBVmin shows a statistically significant difference in OS and PFS between low (rCBVmin < 0.56) and high (rCBVmin ≥ 0.56) groups (P = .01, logrank test for OS; P < .01, logrank test for PFS).
- Fig 2.
Overall survival and progression-free survival probability based on combined ADC and rCBV measurements. A and C, Patient outcome as a function of combined stratification by using ADCmin and rCBVmean. Patients stratified into the low-low group (ADCmin < 384, rCBVmean < 1.43; dashed line), high-high group (ADCmin ≥ 384, rCBVmean ≥ 1.43; solid line), and mixed (low ADCmin and high rCBVmean or high ADCmin and low rCBVmean; dotted line). Kaplan-Meier analysis (A) of OS shows decreased median survival for the low-low group of 7.9 months and a median survival of 36.0 months for the mixed group (P < .01, logrank test). Kaplan-Meier analysis (C) of PFS shows a median progression for the low-low group of 2.5 months and a median progression of 36 months for the mixed group (P < .01, logrank test). C and D, Patient outcome as a function of combined stratification by using ADCmin and rCBVmin: patients stratified into the low-low group (ADCmin < 384, rCBVmin < 0.56; dashed line), high-high group (ADCmin ≥ 384, rCBVmin ≥ 0.56; solid line), and mixed (low ADCmin and high rCBVmin or high ADCmin and low rCBVmin; dotted line). Kaplan-Meier analysis shows statistically significant differences between groups in overall survival and progression (P < .01, logrank test for OS; P < .01, logrank test for PFS).
- Fig 3.
Prognostic survival groups based on individual or combined imaging variables. Overall survival stratification based on ADCmin, rCBVmin, or combined ADCmin–rCBVmin is shown as a boxplot. The survival difference is most marked when comparing the combined low ADCmin–low rCBVmin (low-low) group and the high ADCmin–high rCBVmin (high-high). Similar results are obtained if rCBVmean is used instead of rCBVmin.
Tables
Patient demographics and imaging characteristics
Patient No. Age (yr)/Sex ADCmin × 1012 ADC Group CEL (vol · cm3) Edema (vol · cm3) rCBVmean rCBVmean Group rCBVmin rCBVmin Group 1 80/M 520 High 11.37 108.63 1.02 Low 0.01 Low 2 60/M 618 High 6.26 29.37 1.43 Low 0.40 Low 3 70/F 575 High 12.62 96.00 1.38 Low 0.33 Low 4 58/M 133 Low 49.10 153.20 1.00 Low 0.50 Low 5 74/F 213 Low 43.40 99.30 1.42 Low 0.26 Low 6 59/F 594 High 20.04 72.43 1.17 Low 0.26 Low 7 53/F 236 Low 6.90 62.60 1.15 Low 0.25 Low 8 64/F 631 High 6.39 41.62 1.16 Low 0.52 Low 9 71/F 279 Low 28.89 152.69 1.01 Low 0.27 Low 10 58/F 660 High 18.80 193.90 1.17 Low 0.34 Low 11 76/M 640 High 5.00 26.10 2.82 High 0.18 Low 12 88/M 580 High 14.70 112.60 2.76 High 1.19 High 13 84/M 620 High 14.18 89.76 2.62 High 0.50 Low 14 57/F 528 High 13.90 30.50 1.61 High 0.89 High 15 64/M 260 Low 39.45 218.88 1.67 High 0.02 Low 16 64/F 718 High 11.94 50.49 4.39 High 1.19 High 17 87/F 586 High 4.06 91.71 2.37 High 0.55 Low 18 68/F 1010 High 8.40 19.60 1.80 High 1.16 High 19 74/M 684 High 16.86 130.90 1.79 High 0.22 Low 20 30/M 505 High 29.00 186.10 4.21 High 1.29 High 21 70/F 233 Low 22.60 102.20 1.90 High 0.02 Low 22 83/F 409 High 8.85 94.84 1.97 High 0.38 Low 23 68/M 562 High 22.60 115.20 1.60 High 0.95 High 24 60/F 737 High 3.06 45.38 1.50 High 0.34 Low 25 59/F 318 Low 17.48 56.36 1.72 High 0.59 High
In this issue
Jump to section
Related Articles
Cited By...
- Imaging of Lymphomas Involving the CNS: An Update-Review of the Full Spectrum of Disease with an Emphasis on the World Health Organization Classifications of CNS Tumors 2021 and Hematolymphoid Tumors 2022
- Hypovascular Cellular Tumor in Primary Central Nervous System Lymphoma is Associated with Treatment Resistance: Tumor Habitat Analysis Using Physiologic MRI
- Prognostic Implications of Gadolinium Enhancement of Skull Base Chordomas
- Tumor Uptake of Anti-CD20 Fabs Depends on Tumor Perfusion
- Diffusion-Weighted Imaging for Predicting and Monitoring Primary Central Nervous System Lymphoma Treatment Response
- The Combined Performance of ADC, CSF CXC Chemokine Ligand 13, and CSF Interleukin 10 in the Diagnosis of Central Nervous System Lymphoma
- Improved Brain Tumor Classification by Sodium MR Imaging: Prediction of IDH Mutation Status and Tumor Progression